|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Ontario Clinical Oncology Group (OCOG) Ontario Cancer Research Network |
|---|---|
| Information provided by: | Ontario Clinical Oncology Group (OCOG) |
| ClinicalTrials.gov Identifier: | NCT00201903 |
Purpose
To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma
| Condition |
|---|
|
Venous Thromboembolism Brain Tumors |
| Study Type: | Observational |
| Study Design: | Natural History, Longitudinal, Defined Population, Prospective Study |
| Official Title: | The Roles of Tissue Factor in Malignant Gliomas |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Michigan | |
| Henry Ford Hospital | |
| Detroit, Michigan, United States, 48202 | |
| United States, Utah | |
| Huntsman Cancer Institute | |
| Salt Lake City, Utah, United States, 84112-5550 | |
| Canada, Alberta | |
| Cross Cancer Institute | |
| Edmonton, Alberta, Canada, T6G 1Z2 | |
| Canada, Manitoba | |
| CancerCare Manitoba | |
| Winnipeg, Manitoba, Canada, R3E 0V9 | |
| Canada, Ontario | |
| Princess Margaret Hospital | |
| Toronto, Ontario, Canada, M5G 2M9 | |
| Toronto-Sunnybrook Regional Cancer Centre | |
| Toronto, Ontario, Canada, M4N 3M5 | |
| Study Chair: | Agnes Lee, MD | Hamilton Health Sciences and McMaster University |
| Principal Investigator: | William Geerts, MD | Sunnybrook Health Sciences Centre |
| Principal Investigator: | Mark Levine, MD | Ontario Clinical Oncology Group |
| Principal Investigator: | James Perry, MD | Toronto Sunnybrook Regional Cancer Centre |
| Principal Investigator: | Janusz Rak | Hamilton Health Sciences and McMaster University |
| Principal Investigator: | Jeffrey Weitz, MD | Hamilton Health Sciences and McMaster University |
More Information
| Study ID Numbers: | OCOG-2003-TFsubstudy, NCT00135876 |
| Study First Received: | September 13, 2005 |
| Last Updated: | May 18, 2007 |
| ClinicalTrials.gov Identifier: | NCT00201903 |
| Health Authority: | Canada: Health Canada |
|
venous thromboembolism brain tumours glioma tissue factor |
blood coagulation tumour progression low molecular weight heparin |
|
Heparin, Low-Molecular-Weight Vascular Diseases Disease Progression Central Nervous System Diseases Central Nervous System Neoplasms Venous Thromboembolism Brain Diseases Thrombosis Thromboembolism Calcium heparin Body Weight |
Brain Neoplasms Neuroectodermal Tumors Embolism and Thrombosis Embolism Thromboplastin Neoplasms, Germ Cell and Embryonal Neuroepithelioma Glioma Heparin Nervous System Neoplasms Neoplasms, Glandular and Epithelial |
|
Neoplasms Neoplasms by Histologic Type Neoplasms by Site Coagulants Therapeutic Uses Hematologic Agents |
Neoplasms, Nerve Tissue Nervous System Diseases Cardiovascular Diseases Neoplasms, Neuroepithelial Pharmacologic Actions Hemostatics |
